JoonHo Lee1, Roberto Romero2,3,4,5, Sun Min Kim1,6, Piya Chaemsaithong2,7, Bo Hyun Yoon1. 1. a Department of Obstetrics and Gynecology , Seoul National University College of Medicine , Seoul , Republic of Korea . 2. b Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NICHD/NIH/DHHS , Bethesda, MD, and Detroit, MI , USA . 3. c Department of Obstetrics and Gynecology , University of Michigan , Ann Arbor , MI , USA . 4. d Department of Epidemiology and Biostatistics , Michigan State University , East Lansing , MI , USA . 5. e Center for Molecular Medicine and Genetics, Wayne State University , Detroit , MI , USA . 6. f Department of Obstetrics and Gynecology , Seoul Metropolitan Government --Seoul National University Boramae Medical Center , Seoul , Republic of Korea , and. 7. g Department of Obstetrics and Gynecology , Wayne State University School of Medicine , Detroit , MI , USA.
Abstract
OBJECTIVES: To determine whether a new antibiotic regimen could reduce the frequency of intra-amniotic inflammation/infection in patients with preterm PROM. STUDY DESIGN: This retrospective cohort study was conducted to evaluate the effect of antibiotics on the frequency of intra-amniotic inflammation/infection based on the results of follow-up transabdominal amniocenteses from 89 patients diagnosed with preterm PROM who underwent serial amniocenteses. From 1993-2003, ampicillin and/or cephalosporins or a combination was used ("regimen 1"). A new regimen (ceftriaxone, clarithromycin and metronidazole) was used from 2003-2012 ("regimen 2"). Amniotic fluid was cultured and matrix metalloproteinase-8 (MMP-8) concentrations were measured. RESULTS: (1) The rates of intra-amniotic inflammation and intra-amniotic inflammation/infection in patients who received regimen 2 decreased during treatment from 68.8% to 52.1% and from 75% to 54.2%, respectively. In contrast, in patients who received regimen 1, the frequency of intra-amniotic inflammation and infection/inflammation increased during treatment (31.7% to 55% and 34.1% to 58.5%, respectively); and (2) intra-amniotic inflammation/infection was eradicated in 33.3% of patients who received regimen 2, but in none who received regimen 1. CONCLUSION: The administration of ceftriaxone, clarithromycin and metronidazole was associated with a more successful eradication of intra-amniotic inflammation/infection and prevented secondary intra-amniotic inflammation/infection more frequently than an antibiotic regimen which included ampicillin and/or cephalosporins in patients with preterm PROM.
OBJECTIVES: To determine whether a new antibiotic regimen could reduce the frequency of intra-amniotic inflammation/infection in patients with preterm PROM. STUDY DESIGN: This retrospective cohort study was conducted to evaluate the effect of antibiotics on the frequency of intra-amniotic inflammation/infection based on the results of follow-up transabdominal amniocenteses from 89 patients diagnosed with preterm PROM who underwent serial amniocenteses. From 1993-2003, ampicillin and/or cephalosporins or a combination was used ("regimen 1"). A new regimen (ceftriaxone, clarithromycin and metronidazole) was used from 2003-2012 ("regimen 2"). Amniotic fluid was cultured and matrix metalloproteinase-8 (MMP-8) concentrations were measured. RESULTS: (1) The rates of intra-amniotic inflammation and intra-amniotic inflammation/infection in patients who received regimen 2 decreased during treatment from 68.8% to 52.1% and from 75% to 54.2%, respectively. In contrast, in patients who received regimen 1, the frequency of intra-amniotic inflammation and infection/inflammation increased during treatment (31.7% to 55% and 34.1% to 58.5%, respectively); and (2) intra-amniotic inflammation/infection was eradicated in 33.3% of patients who received regimen 2, but in none who received regimen 1. CONCLUSION: The administration of ceftriaxone, clarithromycin and metronidazole was associated with a more successful eradication of intra-amniotic inflammation/infection and prevented secondary intra-amniotic inflammation/infection more frequently than an antibiotic regimen which included ampicillin and/or cephalosporins in patients with preterm PROM.
Authors: Robert M Ehsanipoor; Judith H Chung; Charlotte A Clock; Jennifer A McNulty; Deborah A Wing Journal: Am J Obstet Gynecol Date: 2008-05 Impact factor: 8.661
Authors: Jantien L van der Heyden; David P van der Ham; Sander van Kuijk; Kim J B Notten; Timothy Janssen; Jan G Nijhuis; Christine Willekes; Martina Porath; Joris A van der Post; Feico Halbertsma; Ben Willem J Mol; Eva Pajkrt Journal: Eur J Obstet Gynecol Reprod Biol Date: 2013-07-08 Impact factor: 2.435
Authors: Roberto Romero; Nardhy Gomez-Lopez; Andrew D Winters; Eunjung Jung; Majid Shaman; Janine Bieda; Bogdan Panaitescu; Percy Pacora; Offer Erez; Jonathan M Greenberg; Madison M Ahmad; Chaur-Dong Hsu; Kevin R Theis Journal: J Perinat Med Date: 2019-11-26 Impact factor: 1.901
Authors: K Motomura; R Romero; V Garcia-Flores; Y Leng; Y Xu; J Galaz; R Slutsky; D Levenson; N Gomez-Lopez Journal: Mol Hum Reprod Date: 2020-09-01 Impact factor: 4.025
Authors: Eunjung Jung; Roberto Romero; Bo Hyun Yoon; Kevin R Theis; Dereje W Gudicha; Adi L Tarca; Ramiro Diaz-Primera; Andrew D Winters; Nardhy Gomez-Lopez; Lami Yeo; Chaur-Dong Hsu Journal: J Perinat Med Date: 2021-07-07 Impact factor: 2.716